Advertisement
U.S. markets closed

Genfit S.A. (XUPB.MU)

Munich - Munich Delayed Price. Currency in EUR
3.50000.0000 (0.00%)
At close: 08:10AM CET

Genfit S.A.

Parc EurasantE
885, avenue EugEne AvinEe
Loos 59120
France
33 3 20 16 40 00
https://www.genfit.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees154

Key Executives

NameTitlePayExercisedYear Born
Mr. Jean-Francois MouneyCo-Founder & Chairman of the Board368.55kN/A1955
Mr. M. Pascal PrigentChief Executive Officer558.54kN/A1968
Prof. Bart StaelsCo-Founder & Chairman of the Scientific Advisory BoardN/AN/A1963
Mr. Thomas BaetzChief Financial OfficerN/AN/A1974
Mr. Pascal CaiseyChief Operating OfficerN/AN/A1968
Dr. Meriam Kabbaj Ph.D.Chief Technology OfficerN/AN/A1974
Dr. Dean W. Hum Ph.D.Chief Scientific Officer710.72kN/A1962
Mr. Jean-Christophe MarcouxChief Corporate Affairs Officer, Head of Investor Relations & Head of ESGN/AN/A1978
Mr. Laurent LannooCorporate Secretary & Director of Legal AffairsN/AN/A1970
Ms. Stefanie Magner J.D.Chief Compliance Officer & Executive VP of International Legal AffairsN/AN/A1981
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Corporate Governance

Genfit S.A.’s ISS Governance QualityScore as of February 1, 2024 is 4. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 5; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.